Scholar Rock Holding Corp (SRRK)

$54.62 -2.80 (-4.88%)
Market Cap 6.99B
Revenue (ttm) 0.00
Net Income (ttm) -377.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.77
Volume 1,601,800
Avg Vol 1,103,662
Day's Range N/A - N/A
Shares Out 121.79M
Stochastic %K 10%
Beta 0.67
Analysts Strong Sell
Price Target $61.00

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that loca...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 3860
Address:
301 Binney Street, 3rd Floor, Cambridge, United States
cheating_stock_trader
cheating_stock_trader Sep. 8 at 4:29 PM
$SRRK should get a nice pop after fda approval. This is a game changer in its respective field. When they start cash flow should be 100+
0 · Reply
Floridaorange
Floridaorange Sep. 1 at 3:33 PM
$SRRK yall following NGEN??
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Aug. 31 at 1:34 AM
Stock Catalysts for September 2026: $RARE — PDUFA Date: September 19 $IONS — PDUFA Date: September 22 $TLX — PDUFA Date: September 11 $SRRK — PDUFA Date: September 30 $ROIV — Q3 2026 Decision Window https://truthsandnews.com/markets/stock-catalysts-september-2026-names-to-watch-now
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 26 at 6:41 PM
$SRRK this will be $70 by the end of the year.
0 · Reply
Shawnnielsen
Shawnnielsen Aug. 26 at 4:25 PM
$SRRK NUT
0 · Reply
Tdorsey1776
Tdorsey1776 Aug. 26 at 3:18 PM
$SRRK Another M&A candidate along with CADL and VRDN
0 · Reply
Thinkingman91
Thinkingman91 Aug. 26 at 1:19 PM
$SRRK I try to help repeatedly, all the time, not many listen
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 25 at 8:19 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 25 at 4:38 PM
$SRRK this is going to be a blockbuster of a drug!
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 24 at 6:35 PM
$SRRK NEW 52 week HIGH!
0 · Reply
Latest News on SRRK
Scholar Rock Holding Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 9, 2026, 8:00 AM EDT - 22 hours ago

Scholar Rock Holding Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Scholar Rock receives fast track designation from FDA for apitegromab

2026-09-02T12:06:07.000Z - 7 days ago

Scholar Rock receives fast track designation from FDA for apitegromab

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Sep 2, 2026, 8:00 AM EDT - 7 days ago

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (FSHD) Program as Participant Dosing Commences in Phase 2 FORGE Trial

Scholar Rock to Present at Upcoming Investor Conferences

Aug 27, 2026, 8:00 AM EDT - 13 days ago

Scholar Rock to Present at Upcoming Investor Conferences

Scholar Rock price target raised to $64 from $58 at Wedbush

2026-08-21T15:40:15.000Z - 19 days ago

Scholar Rock price target raised to $64 from $58 at Wedbush

Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission

Aug 21, 2026, 10:47 AM EDT - 19 days ago

Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

2026-08-21T13:10:15.000Z - 19 days ago

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

NVO

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Aug 21, 2026, 9:06 AM EDT - 19 days ago

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

Scholar Rock price target raised to $63 from $56 at JPMorgan

2026-08-17T07:59:33.000Z - 24 days ago

Scholar Rock price target raised to $63 from $56 at JPMorgan

Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status

2026-08-17T07:25:35.000Z - 24 days ago

Scholar Rock facioscapulohumeral muscular dystrophy treatment gets orphan status

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 14, 2026, 4:15 PM EDT - 26 days ago

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference

Aug 12, 2026, 1:30 PM EDT - 4 weeks ago

Scholar Rock Holding Transcript: Canaccord Genuity's 46th Annual Growth Conference

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Aug 7, 2026, 5:29 PM EDT - 4 weeks ago

Scholar Rock drops Catalent facility from marketing application for muscle weakness drug

Scholar Rock to remove Catalent Indiana facility from apitegromab BLA

2026-08-07T20:30:42.000Z - 4 weeks ago

Scholar Rock to remove Catalent Indiana facility from apitegromab BLA

NVO

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Aug 7, 2026, 4:20 PM EDT - 4 weeks ago

Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date

Scholar Rock price target raised to $76 from $70 at BMO Capital

2026-08-07T12:01:51.000Z - 4 weeks ago

Scholar Rock price target raised to $76 from $70 at BMO Capital

Scholar Rock price target raised to $60 from $58 at Citi

2026-08-07T11:07:02.000Z - 4 weeks ago

Scholar Rock price target raised to $60 from $58 at Citi

Scholar Rock Holding Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 4 weeks ago

Scholar Rock Holding Earnings Call Transcript: Q2 2026

Scholar Rock Holding Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 4 weeks ago

Scholar Rock Holding Earnings release: Q2 2026

Scholar Rock Holding Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 4 weeks ago

Scholar Rock Holding Quarterly report: Q2 2026

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 6, 2026, 7:00 AM EDT - 4 weeks ago

Scholar Rock Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Jul 29, 2026, 8:00 AM EDT - 6 weeks ago

Scholar Rock to Present at the Canaccord Genuity 46th Annual Growth Conference

Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026

Jul 20, 2026, 11:40 AM EDT - 7 weeks ago

Scholar Rock says EU opinion on SMA drug may be pushed to later in 2026

Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA

2026-07-20T12:10:31.000Z - 7 weeks ago

Scholar Rock provides update on timing of CHMP opinion for apitegromab MAA

NVO

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Jul 20, 2026, 8:00 AM EDT - 7 weeks ago

Scholar Rock Provides Update on Timing of Committee for Medicinal Products for Human Use (CHMP) Opinion for Apitegromab Marketing Authorisation Application (MAA) for Spinal Muscular Atrophy (SMA)

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 16, 2026, 8:00 AM EDT - 7 weeks ago

Scholar Rock to Report Second Quarter 2026 Financial Results on August 6, 2026

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

Jun 22, 2026, 8:00 AM EDT - 2 months ago

Scholar Rock to Showcase Neuromuscular Research Portfolio at 2026 Annual Cure SMA Research and Clinical Care Meeting and 2026 International Research Congress on FSHD

SMA

Scholar Rock Holding Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 10:00 AM EDT - 3 months ago

Scholar Rock Holding Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Scholar Rock Holding Transcript: AGM 2026

Jun 4, 2026, 12:00 PM EDT - 3 months ago

Scholar Rock Holding Transcript: AGM 2026

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 11:40 AM EDT - 3 months ago

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2026

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

May 26, 2026, 9:30 AM EDT - 3 months ago

Scholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

May 20, 2026, 8:00 AM EDT - 3 months ago

Scholar Rock to Present at the 2026 Jefferies Global Healthcare Conference

Scholar Rock Holding Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 11:00 AM EDT - 4 months ago

Scholar Rock Holding Transcript: Bank of America Global Healthcare Conference 2026

JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’

2026-05-08T13:33:22.000Z - 4 months ago

JPMorgan places Scholar Rock on ‘Positive Catalyst Watch’

Scholar Rock price target raised to $55 from $53 at Barclays

2026-05-08T10:58:07.000Z - 4 months ago

Scholar Rock price target raised to $55 from $53 at Barclays

Scholar Rock price target raised to $65 from $58 at H.C. Wainwright

2026-05-08T10:39:43.000Z - 4 months ago

Scholar Rock price target raised to $65 from $58 at H.C. Wainwright

Scholar Rock Holding Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Earnings Call Transcript: Q1 2026

Scholar Rock Holding Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Earnings release: Q1 2026

Scholar Rock Holding Quarterly report: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Quarterly report: Q1 2026

Scholar Rock Holding Slides: Q1 2026

May 7, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Slides: Q1 2026

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026, 7:00 AM EDT - 4 months ago

Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Apr 29, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock to Present at the BofA Securities 2026 Health Care Conference

Scholar Rock Holding Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Proxy statement: Proxy filing

Scholar Rock Holding Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock Holding Proxy statement: Proxy filing

Scholar Rock initiated with a Buy at Canaccord

2026-04-21T09:11:03.000Z - 4 months ago

Scholar Rock initiated with a Buy at Canaccord

Scholar Rock initiated with a Buy at Canaccord

2026-04-20T20:42:45.000Z - 4 months ago

Scholar Rock initiated with a Buy at Canaccord

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 16, 2026, 8:00 AM EDT - 4 months ago

Scholar Rock to Report First Quarter 2026 Financial Results on May 7, 2026

Scholar Rock price target raised to $57 from $54 at Jefferies

2026-04-01T16:50:15.000Z - 5 months ago

Scholar Rock price target raised to $57 from $54 at Jefferies

Scholar Rock price target raised to $58 from $51 at BofA

2026-03-31T16:50:34.000Z - 5 months ago

Scholar Rock price target raised to $58 from $51 at BofA

Scholar Rock resubmission ‘material de-risking event,’ says H.C. Wainwright

2026-03-31T15:41:40.000Z - 5 months ago

Scholar Rock resubmission ‘material de-risking event,’ says H.C. Wainwright

Scholar Rock Holding Transcript: Status update

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Scholar Rock Holding Transcript: Status update

Scholar Rock Holding Press release: Status update

Mar 31, 2026, 8:00 AM EDT - 5 months ago

Scholar Rock Holding Press release: Status update

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Mar 31, 2026, 7:00 AM EDT - 5 months ago

Scholar Rock Resubmits Biologics License Application (BLA) to FDA for Apitegromab for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

Scholar Rock Holding Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 12, 2026, 8:30 AM EDT - 6 months ago

Scholar Rock Holding Transcript: Barclays 28th Annual Global Healthcare Conference

Scholar Rock Holding Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:30 PM EDT - 6 months ago

Scholar Rock Holding Transcript: Leerink Global Healthcare Conference 2026

Scholar Rock Holding Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 1:50 PM EST - 6 months ago

Scholar Rock Holding Transcript: TD Cowen 46th Annual Health Care Conference

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 3, 2026, 3:26 PM EST - 6 months ago

CORRECTING and REPLACING Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Scholar Rock Holding Earnings Call Transcript: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Scholar Rock Holding Earnings Call Transcript: Q4 2025

Scholar Rock Holding Annual report: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Scholar Rock Holding Annual report: Q4 2025

Scholar Rock Holding Earnings release: Q4 2025

Mar 3, 2026, 8:00 AM EST - 6 months ago

Scholar Rock Holding Earnings release: Q4 2025

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Mar 3, 2026, 7:00 AM EST - 6 months ago

Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Feb 10, 2026, 8:00 AM EST - 7 months ago

Scholar Rock to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026

Scholar Rock Holding Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 8 months ago

Scholar Rock Holding Transcript: 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock Holding Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 10:30 AM EST - 8 months ago

Scholar Rock Holding Slides: 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock Highlights 2026 Strategic Priorities

Jan 12, 2026, 7:00 AM EST - 8 months ago

Scholar Rock Highlights 2026 Strategic Priorities

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 8:00 AM EST - 8 months ago

Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Scholar Rock Holding Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 8:20 AM EST - 9 months ago

Scholar Rock Holding Transcript: Evercore ISI 8th Annual HealthCONx Conference

Scholar Rock Holding Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 1:00 PM EST - 9 months ago

Scholar Rock Holding Transcript: Citi Annual Global Healthcare Conference 2025

Scholar Rock Holding Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 10:30 AM EST - 9 months ago

Scholar Rock Holding Transcript: Jefferies London Healthcare Conference 2025

Scholar Rock Holding Earnings Call Transcript: Q3 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Scholar Rock Holding Earnings Call Transcript: Q3 2025

Scholar Rock Holding Quarterly report: Q3 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Scholar Rock Holding Quarterly report: Q3 2025

Scholar Rock Holding Earnings release: Q3 2025

Nov 14, 2025, 8:00 AM EST - 9 months ago

Scholar Rock Holding Earnings release: Q3 2025

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov 14, 2025, 7:00 AM EST - 9 months ago

Scholar Rock Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Nov 4, 2025, 8:00 AM EST - 10 months ago

Scholar Rock to Present at the 2025 Jefferies Global Healthcare Conference

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

Oct 23, 2025, 8:00 AM EDT - 10 months ago

Scholar Rock to Report Third Quarter 2025 Financial Results on November 14, 2025

US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:12 AM EDT - 11 months ago

US FDA declines to approve Scholar Rock's muscle weakness drug

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Sep 23, 2025, 7:00 AM EDT - 11 months ago

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Aug 14, 2025, 8:00 AM EDT - 1 year ago

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

Scholar Rock Holding Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Earnings Call Transcript: Q2 2025

Scholar Rock Holding Quarterly report: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Quarterly report: Q2 2025

Scholar Rock Holding Earnings release: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Earnings release: Q2 2025

Scholar Rock Holding Slides: Q2 2025

Aug 6, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Slides: Q2 2025

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Aug 6, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Jul 21, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Scholar Rock Holding Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Holding Slides: Corporate Presentation

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Jun 24, 2025, 6:25 PM EDT - 1 year ago

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Scholar Rock Holding Transcript: Study Update

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Transcript: Study Update

Scholar Rock Holding Press release: Study Update

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Press release: Study Update

Scholar Rock Holding Slides: Study Update

Jun 18, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Slides: Study Update

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Jun 18, 2025, 7:33 AM EDT - 1 year ago

Scholar Rock Shares Jump on Positive Results from Weight Loss Trial

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:12 AM EDT - 1 year ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Scholar Rock Holding Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 11, 2025, 9:20 AM EDT - 1 year ago

Scholar Rock Holding Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Jun 5, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 3:45 PM EDT - 1 year ago

Scholar Rock Holding Transcript: Jefferies Global Healthcare Conference 2025

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Jun 2, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Appoints Rebecca McLeod Chief Brand Officer and U.S. General Manager

Scholar Rock to Present at the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Present at the Jefferies Global Healthcare Conference

Scholar Rock Holding Earnings Call Transcript: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Earnings Call Transcript: Q1 2025

Scholar Rock Holding Quarterly report: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Quarterly report: Q1 2025

Scholar Rock Holding Earnings release: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Earnings release: Q1 2025

Scholar Rock Holding Slides: Q1 2025

May 14, 2025, 8:15 AM EDT - 1 year ago

Scholar Rock Holding Slides: Q1 2025

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

May 14, 2025, 7:00 AM EDT - 1 year ago

Scholar Rock Reports First Quarter 2025 Financial Results and Highlights Business Progress

Scholar Rock Holding Proxy statement: Proxy Filing

May 12, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

May 7, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock to Host Conference Call to Discuss First Quarter 2025 Financial Results and Provide Business Update on May 14, 2025

Scholar Rock Holding Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Apr 28, 2025, 6:50 AM EDT - 1 year ago

Scholar Rock Appoints David L. Hallal as Chief Executive Officer; Also Announces Addition of Three Key Leaders to Scale for Next Phase of Growth

Scholar Rock Holding Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

Scholar Rock Holding Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Scholar Rock Holding Proxy statement: Proxy Filing

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Mar 25, 2025, 7:30 AM EDT - 1 year ago

FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Mar 16, 2025, 7:00 PM EDT - 1 year ago

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

Scholar Rock Holding Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 2:30 PM EST - 1 year ago

Scholar Rock Holding Transcript: TD Cowen 45th Annual Healthcare Conference

Scholar Rock Holding Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Earnings Call Transcript: Q4 2024

Scholar Rock Holding Annual report: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Annual report: Q4 2024

Scholar Rock Holding Earnings release: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Earnings release: Q4 2024

Scholar Rock Holding Slides: Q4 2024

Feb 27, 2025, 8:15 AM EST - 1 year ago

Scholar Rock Holding Slides: Q4 2024

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Feb 27, 2025, 7:00 AM EST - 1 year ago

Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:15 PM EST - 1 year ago

Scholar Rock to Participate in Upcoming Investor Conferences

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Feb 21, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

Feb 19, 2025, 10:41 AM EST - 1 year ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

Feb 10, 2025, 8:00 AM EST - 1 year ago

Scholar Rock to Host Conference Call to Discuss Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Update on February 27, 2025

cheating_stock_trader
cheating_stock_trader Sep. 8 at 4:29 PM
$SRRK should get a nice pop after fda approval. This is a game changer in its respective field. When they start cash flow should be 100+
0 · Reply
Floridaorange
Floridaorange Sep. 1 at 3:33 PM
$SRRK yall following NGEN??
0 · Reply
TNNStockAnalysisNews
TNNStockAnalysisNews Aug. 31 at 1:34 AM
Stock Catalysts for September 2026: $RARE — PDUFA Date: September 19 $IONS — PDUFA Date: September 22 $TLX — PDUFA Date: September 11 $SRRK — PDUFA Date: September 30 $ROIV — Q3 2026 Decision Window https://truthsandnews.com/markets/stock-catalysts-september-2026-names-to-watch-now
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 26 at 6:41 PM
$SRRK this will be $70 by the end of the year.
0 · Reply
Shawnnielsen
Shawnnielsen Aug. 26 at 4:25 PM
$SRRK NUT
0 · Reply
Tdorsey1776
Tdorsey1776 Aug. 26 at 3:18 PM
$SRRK Another M&A candidate along with CADL and VRDN
0 · Reply
Thinkingman91
Thinkingman91 Aug. 26 at 1:19 PM
$SRRK I try to help repeatedly, all the time, not many listen
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 25 at 8:19 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 25 at 4:38 PM
$SRRK this is going to be a blockbuster of a drug!
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 24 at 6:35 PM
$SRRK NEW 52 week HIGH!
0 · Reply
StocktwitsNews
StocktwitsNews Aug. 21 at 9:50 PM
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing $SRRK $VTI $IWM $NVO https://stocktwits.com/news/equity/markets/srrk-stock-gains-after-company-drops-troubled-novo-nordisk-owned-plant-from-fda-filing/cZY97AgRJVf
0 · Reply
TwongStocks
TwongStocks Aug. 21 at 1:15 PM
$SRRK Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan https://www.businesswire.com/news/home/20260821050366/en/Scholar-Rock-Provides-Update-on-Global-Apitegromab-Regulatory-Progress-Across-U.S.-Europe-and-Japan • Under FDA guidance, Scholar Rock has successfully removed Catalent Indiana LLC (part of Novo Nordisk) as a commercial fill-finish facility from apitegromab BLA. FDA review of BLA progressing well with Scholar Rock’s alternate fill-finish facility. PDUFA date Sept 30 • In alignment with European Medicines Agency (EMA), Scholar Rock has withdrawn apitegromab MAA and will resubmit with alternate fill-finish facility to facilitate most expeditious path to CHMP opinion • Apitegromab Japanese New Drug Application (JNDA) submission by YE 2026
0 · Reply
Thinkingman91
Thinkingman91 Aug. 18 at 10:38 PM
$SRRK this is my stock with the largest potential. Also one of the few I called wrong it never came back. This will be multiple of 100s
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 10 at 11:01 PM
$SRRK can you say ready….set…GO!
0 · Reply
prismmarketview
prismmarketview Aug. 10 at 6:53 PM
$SRRK Scholar Rock’s apitegromab BLA review is advancing through a second fill-finish facility, with the FDA data package submitted ahead of schedule. Scholar Rock says it has commercial supply ready and continues to target a potential approval decision by September 30. https://prismmarketview.com/scholar-rock-advances-apitegromab-fda-review-for-spinal-muscular-atrophy/
0 · Reply
TwongStocks
TwongStocks Aug. 7 at 8:25 PM
$SRRK Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date https://www.businesswire.com/news/home/20260807011647/en/Scholar-Rock-Announces-FDA-Review-of-Apitegromab-Biologics-License-Application-BLA-for-Spinal-Muscular-Atrophy-SMA-to-Progress-with-Second-Fill-Finish-Facility-Approval-Decision-Anticipated-by-September-30-2026-Action-Date • The FDA has classified the April 2026 site inspection of Catalent Indiana as Official Action Indicated (OAI). • Scholar Rock will continue to collaborate closely with the FDA and under their guidance, will remove Catalent Indiana from the apitegromab BLA. • FDA review of the apitegromab BLA will progress solely with the second fill-finish facility.
1 · Reply
Tdorsey1776
Tdorsey1776 Aug. 6 at 6:20 PM
$SRRK Was hoping the ATM offering would cause selloff to add more. GLTA
1 · Reply
EarningsInsider
EarningsInsider Aug. 6 at 1:32 PM
https://www.marketbeat.com/earnings/reports/2026-8-6-scholar-rock-holding-co-stock/ $SRRK Scholar Rock Earnings Transcript
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Aug. 6 at 12:53 PM
$SRRK Q2 '26 Earnings Results & Recap Reported GAAP EPS of -$0.84 up 14.29% YoY
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:13 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:12 PM
$SRRK
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Aug. 6 at 12:10 PM
$SRRK
0 · Reply